The study surveyed over 1,600 individuals across 58 countries who self-reported a clinical diagnosis of endometriosis. Participants detailed their use of various therapies, with a specific focus on the efficacy of cannabis compared to standard pharmaceutical interventions. Notably, cannabis received higher ratings than any other medication or therapy in providing relief for chronic pelvic pain, gastrointestinal symptoms, and mood disturbances—three of the most common complaints associated with endometriosis.
Participants reported that cannabis not only alleviated multiple symptoms simultaneously but also improved overall quality of life with fewer adverse effects than prescription medications. Over 80% of respondents indicated that cannabis was “very” or “moderately effective,” with many citing a significant reduction in their reliance on opioids, hormonal treatments, and non-steroidal anti-inflammatory drugs (NSAIDs).
Despite the positive outcomes, the study also highlighted persistent barriers to access, including cost, stigma, and legal restrictions in various regions. Researchers emphasized the urgent need for further clinical trials to validate these findings and develop standardized guidelines for the safe and effective medical use of cannabis in endometriosis treatment.
The results underscore a shift in patient behavior and treatment preferences, pointing to cannabis as a promising complementary or alternative therapy for one of the most painful and poorly understood gynecological conditions worldwide.
Dabbin-Dad Newsroom
If you liked this post, say thanks by sharing it
